$heff's $tation of $tocks & $olid DD

[$heff]

TLON..$.90 I mention in my post that for enrollment of Talon's confirmatory trial that Talon is waiting for a 3rd-6th line patients. The patient population for the confirmatory trial is different than the RALLY study. The Phase 3 study is for patients 60 years or older with newly diagnosed ALL. I wanted to clarify as I was not clear in my earlier message that these are two separate trials. I am still awaiting the first patient enrollment from the HALLMARQ study.

Talon states that the Phase 3 confirmatory trial (Hallmarq) primary objective is:

"To compare overall survival (OS) among subjects 60 years of age and older with newly diagnosed ALL who receive Marqibo versus standard vincristine as a component of multi-agent induction, intensification, and maintenance chemotherapy. The study is powered for superiority."